Durability of single-dose rVSV-ZEBOV vaccine responses: what do we know?

Expert Rev Vaccines. 2018 Dec;17(12):1105-1110. doi: 10.1080/14760584.2018.1546582. Epub 2018 Nov 15.


Introduction: The live-attenuated recombinant vesicular stomatitis virus vaccine expressing the glycoprotein (GP) of Zaire Ebola virus (rVSV-ZEBOV) has proven immunogenic in humans and effective in field studies. Yet long-term durability of vaccine responses is unknown.

Areas covered: We survey the evidence available in the literature for the durability of human responses to rVSV-ZEBOV. We also review determinants of initial responses and of their persistence.

Expert commentary: Persistence of EBOV-GP-specific antibody responses is strong at 2 years - currently the longest post-vaccination interval studied - after a single injection. Vaccine dose predicts persistence of seropositivity, though the magnitude of antibody responses at later time points becomes less dose-dependent. Vaccine-related arthritis is a significant predictor of both persistence and magnitude of the antibody response.

Keywords: Ebola vaccine; Ebola virus disease; durability; immune response; persistence; rVSV-ZEBOV vaccine; seropositivity.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antibody Formation / immunology
  • Ebola Vaccines / administration & dosage*
  • Ebola Vaccines / immunology
  • Ebolavirus / immunology
  • Hemorrhagic Fever, Ebola / immunology*
  • Hemorrhagic Fever, Ebola / prevention & control
  • Humans
  • Immunogenicity, Vaccine / immunology
  • Time Factors
  • Vaccination / methods*
  • Vaccines, Attenuated / immunology


  • Ebola Vaccines
  • Vaccines, Attenuated